Loading
Urinary Tract Infections Management / Reproductive Tract Infections Research / Bladder and Urothelial Cancer Treatments · Journal article
PLOS Pathogens · August 13, 2026
A consensus or society position rather than new primary data.
This is an expert commentary endorsing nitrofurantoin as first-line therapy for acute uncomplicated cystitis in women, supported by guideline recommendations (AUA/CUA/SUFU, IDSA), noninferiority demonstrated in systematic reviews and meta-analyses, and recent RCT data suggesting superior efficacy to fosfomycin monodose. The recommendation is grounded in nitrofurantoin's favorable pharmacokinetics (high urine concentration, minimal serum/tissue levels) and low resistance rates.
Journal article. Women with acute uncomplicated simple cystitis.
Nitrofurantoin designated first-line agent by AUA/CUA/SUFU and IDSA guidelines for acute uncomplicated cystitis in women Large systematic reviews and meta-analyses demonstrate nitrofurantoin is noninferior to other commonly prescribed antibiotics for UTI treatment Recent randomized controlled trial suggests 5-day nitrofurantoin course may be more effective than single-dose fosfomycin in UTI treatment
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should use nitrofurantoin as first-line empiric therapy for uncomplicated UTI in women, reflecting guideline consensus and evidence of noninferiority or superiority to alternatives. The agent's minimized collateral effect on commensal microbiota and low resistance rates further support this choice over broader-spectrum agents.
This is an expert commentary on guideline recommendations and existing evidence for nitrofurantoin in UTI treatment, synthesizing published trials and meta-analyses rather than reporting new primary data.
Quoted from the source exactly as published.
Clinicians should use nitrofurantoin as first-line empiric therapy for uncomplicated UTI in women, reflecting guideline consensus and evidence of noninferiority or superiority to alternatives. The agent's minimized collateral effect on commensal microbiota and low resistance rates further support this choice over broader-spectrum agents.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Nitrofurantoin is considered a first-line antimicrobial agent by the AUA/CUA/SUFU Guideline and Infectious Disease Society of America (IDSA) Guideline for the treatment of acute uncomplicated simple cystitis in women. Nitrofurantoin has good oral bioavailability, high concentration in urine, and low serum and tissue concentrations. These characteristics result in minimal collateral damage to the microbial composition of other niches within the human body, such as the gut, that are essential in maintaining homeostasis. In addition, resistance to nitrofurantoin is uncommon owing to its interference with multiple bacterial cellular functions critical to survival. Large systematic reviews and meta-analyses have demonstrated that nitrofurantoin is noninferior to other commonly prescribed antibiotics for treatment of urinary tract infection (UTI). Recent data from a randomized controlled trial suggest that a 5-day course of nitrofurantoin may be more effective than a single dose of fosfomycin in the treatment of UTI. Therefore, nitrofurantoin is an ideal first-line agent in the management of UTI.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.